References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492.
- Wark PA, Peto J. Cancer Epidemiology. Int Encycl Public Heal. Health (Second Edition). Oxford: Academic Press. 2016. pp. 339–346. doi:https://doi.org/10.1016/B978-0-12-803678-5.00048-5.
- Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–713. doi:https://doi.org/10.1158/1055-9965.EPI-13-1057.
- Alfarouk KO, Bashir AHH, Aljarbou AN, et al. The possible role of helicobacter pylori in gastric cancer and its management. Front Oncol. 2019;9:75. doi:https://doi.org/10.3389/fonc.2019.00075/full.
- Wroblewski LE, Peek RM. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42(2):285–298. https://linkinghub.elsevier.com/retrieve/pii/S0889855313000241. doi:https://doi.org/10.1016/j.gtc.2013.01.006.
- Zhu R, Gao C, Wang L, et al. Involvement of aryl hydrocarbon receptor and aryl hydrocarbon receptor repressor in Helicobacter pylori-related gastric pathogenesis. J Cancer. 2018;9(15):2757–2764. http://www.jcancer.org/v09p2757.htm. doi:https://doi.org/10.7150/jca.26083.
- Feng S, Cao Z, Wang X. Biochimica et biophysica acta role of aryl hydrocarbon receptor in cancer. BBA - Rev Cancer. 2013;1836:197–210.
- Moura-Alves P, Faé K, Houthuys E, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature. 2014;512(7515):387–392. doi:https://doi.org/10.1038/nature13684.
- Dantsuka A, Ichii O, Hanberg A, et al. Histopathological features of the proper gastric glands in FVB/N-background mice carrying constitutively-active aryl-hydrocarbon receptor. BMC Gastroenterol. 2019;19(1):102. doi:https://doi.org/10.1186/s12876-019-1009-x.
- Andersson P, McGuire J, Rubio C, et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A. 2002;99(15):9990–9995. doi:https://doi.org/10.1073/pnas.152706299.
- Peng T-L, Chen J, Mao W, et al. Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World J Gastroenterol. 2009;15(14):1719–1729. doi:https://doi.org/10.3748/wjg.15.1719.
- Xue P, Fu J, Zhou Y. The aryl hydrocarbon receptor and tumor immunity [Internet]. Front Immunol. 2018; 9:286. doi:https://doi.org/10.3389/fimmu.2018.00286.
- Seok S-H, Ma Z-X, Feltenberger JB, et al. Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem. 2018;293(6):1994–2005. 2017/12/26. https://pubmed.ncbi.nlm.nih.gov/29279331. doi:https://doi.org/10.1074/jbc.RA117.000631.
- Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435–5440. doi:https://doi.org/10.1158/0008-5472.CAN-12-0569.
- Haruki H, Hovius R, Pedersen MG, et al. Tetrahydrobiopterin biosynthesis as a potential target of the kynurenine pathway metabolite xanthurenic acid. J Biol Chem. 2016;291(2):652–657. /12. https://pubmed.ncbi.nlm.nih.gov/26565027. doi:https://doi.org/10.1074/jbc.C115.680488.
- Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011;438(3):397–414. doi:https://doi.org/10.1042/BJ20110293.
- Cronin SJF, Seehus C, Weidinger A, et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018;563(7732):564–568. doi:https://doi.org/10.1038/s41586-018-0701-2.
- Lee I, Kim S, Nagar H, et al. CR6-interacting factor 1 deficiency reduces endothelial nitric oxide synthase activity by inhibiting biosynthesis of tetrahydrobiopterin. Sci Rep. 2020;10(1):842. doi:https://doi.org/10.1038/s41598-020-57673-9.
- Chaturvedi R, De Sablet T, Coburn LA, et al. Arginine and polyamines in Helicobacter pylori-induced immune dysregulation and gastric carcinogenesis. Amino Acids. 2012;42(2–3):627–640. doi:https://doi.org/10.1007/s00726-011-1038-4.
- Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20(4):633–649. doi:https://doi.org/10.1016/j.bpg.2006.04.008.
- Park JY, Forman D, Waskito LA, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins (Basel). 2018;10(4):163. doi:https://doi.org/10.3390/toxins10040163.
- Tsugane S, Sasazuki S, Kobayashi M, et al. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer. 2004;90(1):128–134. [Database] doi:https://doi.org/10.1038/sj.bjc.6601511.
- Hung N, Shen CC, Hu YW, et al. Risk of cancer in patients with iron deficiency anemia: a nationwide population-based study. PLoS One. 2015;10(3):e0119647–11. doi:https://doi.org/10.1371/journal.pone.0119647.
- Kim MH, Kim SA, Park CH, et al. Alcohol consumption and gastric cancer risk in Korea: a case-control study. Nutr Res Pract. 2019;13(5):425–433. https://europepmc.org/articles/PMC6760983. doi:https://doi.org/10.4162/nrp.2019.13.5.425.
- Mitchell A, Silva TMJ, Barrett LJ, et al. Age-specific Helicobacter pylori seropositivity rates of children in an impoverished urban area of northeast Brazil. J Clin Microbiol. 2003;41(3):1326–1328. doi:https://doi.org/10.1128/jcm.41.3.1326-1328.2003.
- Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1–27. doi:https://doi.org/10.1093/oxfordjournals.epirev.a036288.
- Goh K-L, Chan W-K, Shiota S, et al. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011;16:1–9. doi:https://doi.org/10.1111/j.1523-5378.2011.00874.x.
- Magalhaes Queiroz DM, Luzza F. Epidemiology of Helicobacter pylori Infection. Helicobacter. 2006;11(s1):1–5. doi:https://doi.org/10.1111/j.1478-405X.2006.00429.x.
- Gombart AF, Pierre A, Maggini S. A review of micronutrients and the immune system–working in harmony to reduce the risk of infection. Nutrients. 2020;12(1):236. doi:https://doi.org/10.3390/nu12010236.
- Waskito LA, Salama NR, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2018;23:e12516–14. doi:https://doi.org/10.1111/hel.12516.
- Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4):e12386. Available from: https://pubmed.ncbi.nlm.nih.gov/28402047.
- Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest. 2001;107(7):767–773. doi:https://doi.org/10.1172/JCI12672.
- Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med. 2000;191(4):587–592. doi:https://doi.org/10.1084/jem.191.4.587.
- Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A. 1996;93(25):14648–14653. http://www.ncbi.nlm.nih.gov/pubmed/8962108. doi:https://doi.org/10.1073/pnas.93.25.14648.
- Chaturvedi R, Asim M, Romero–Gallo J, et al. Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gastroenterology [Internet. 2011;141(5):1696–1708.e2. https://linkinghub.elsevier.com/retrieve/pii/S0016508511010808. doi:https://doi.org/10.1053/j.gastro.2011.07.045.
- Buti L, Spooner E, Van der Veen AG, et al. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A. 2011;108(22):9238–9243. doi:https://doi.org/10.1073/pnas.1106200108.
- Saadat I, Higashi H, Obuse C, et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007;447(7142):330–333. http://www.ncbi.nlm.nih.gov/pubmed/17507984. doi:https://doi.org/10.1038/nature05765.
- Eslami M, Yousefi B, Kokhaei P, et al. Current information on the association of Helicobacter pylori with autophagy and gastric cancer. J Cell Physiol. 2019;234(9):14800–14811. doi:https://doi.org/10.1002/jcp.28279.
- Lu H-S, Saito Y, Umeda M, et al. Structural and functional diversity in the PAR1b/MARK2-binding region of Helicobacter pylori CagA. Cancer Sci. 2008;99(10):2004–2011. doi:https://doi.org/10.1111/j.1349-7006.2008.00950.x.
- Nagy TA, Wroblewski LE, Wang D, et al. β-catenin and p120 mediate PPARδ-dependent proliferation induced by helicobacter pylori in human and rodent epithelia. Gastroenterology. 2011;141(2):553–564. doi:https://doi.org/10.1053/j.gastro.2011.05.004.
- Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest. 2010;120(5):1645–1662. doi:https://doi.org/10.1172/JCI39481.
- Nagy TA, Frey MR, Yan F, et al. Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling. J Infect Dis. 2009;199(5):641–651. doi:https://doi.org/10.1086/596660.
- Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 2005;3(4):320–332. doi:https://doi.org/10.1038/nrmicro1095.
- Larussa T, Leone I, Suraci E, et al. Helicobacter pylori and T helper cells: mechanisms of immune escape and tolerance. J Immunol Res. 2015;2015:1–10. doi:https://doi.org/10.1155/2015/981328.
- Tan GMY, Looi CY, Fernandez KC, et al. Suppression of cell division-associated genes by Helicobacter pylori attenuates proliferation of RAW264.7 monocytic macrophage cells. Sci Rep. 2015;5:11046. doi:https://doi.org/10.1038/srep11046.
- Oldani A, Cormont M, Hofman V, et al. Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells. PLoS Pathog. 2009;5(10):e1000603. doi:https://doi.org/10.1371/journal.ppat.1000603.
- Tan S, Noto JM, Romero-Gallo J, et al. Helicobacter pylori perturbs iron trafficking in the epithelium to grow on the cell surface. PLoS Pathog. 2011;7(5):e1002050. doi:https://doi.org/10.1371/journal.ppat.1002050.
- Noto JM, Gaddy JA, Lee JY, et al. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest. 2013;123(1):479–492. doi:https://doi.org/10.1172/JCI64373.
- Yao X, Liu D, Zhou L, et al. FAM60A, increased by Helicobacter pylori, promotes proliferation and suppresses apoptosis of gastric cancer cells by targeting the PI3K/AKT pathway. Biochem Biophys Res Commun. 2020;521(4):1003–1009. doi:https://doi.org/10.1016/j.bbrc.2019.11.029.
- Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol. 1994;29(5):425–429. doi:https://doi.org/10.3109/00365529409096833.
- Santos JC, Ladeira MSP, Pedrazzoli J, et al. Relationship of IL-1 and TNF-α polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. Braz J Med Biol Res. 2012;45(9):811–817. doi:https://doi.org/10.1590/s0100-879x2012007500099.
- El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402. doi:https://doi.org/10.1038/35006081.
- Sugimoto M, Furuta T, Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol. 2009;24(11):1725–1732. https://pubmed.ncbi.nlm.nih.gov/20136959. doi:https://doi.org/10.1111/j.1440-1746.2009.06047.x.
- Guo Y, Zhang T, Shi Y, et al. Helicobacter pylori inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway. Helicobacter. 2020;25(1):e12665. doi:https://doi.org/10.1111/hel.12665.
- Yoon JH, Seo HS, Choi SS, et al. Gastrokine 1 inhibits the carcinogenic potentials of Helicobacter pylori CagA. Carcinogenesis. 2014;35(11):2619–2629. doi:https://doi.org/10.1093/carcin/bgu199.
- Hahn ME. Aryl hydrocarbon receptors: diversity and evolution. Chem Biol Interact. 2002;141(1–2):131–160. https://linkinghub.elsevier.com/retrieve/pii/S0009279702000704. doi:https://doi.org/10.1016/S0009-2797(02)00070-4.
- Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2008;21(1):102–116. doi:https://doi.org/10.1021/tx7001965.
- Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–334. doi:https://doi.org/10.1146/annurev.pharmtox.43.100901.135828.
- Liao LM, Hofmann JN, Kamangar F, et al. Polycyclic aromatic hydrocarbons and risk of gastric cancer in the Shanghai Women’s Health Study. Int J Mol Epidemiol Genet. 2014;5:140–144. https://pubmed.ncbi.nlm.nih.gov/25379133.
- Matthews J, Wihlén B, Thomsen J, et al. Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters. Mol Cell Biol. 2005;25(13):5317–5328. doi:https://doi.org/10.1128/MCB.25.13.5317-5328.2005.
- Xu C, Li CY, Kong AT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28(3):249–268. doi:https://doi.org/10.1007/BF02977789.
- Köhle C, Bock KW. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol. 2007;73(12):1853–1862. doi:https://doi.org/10.1016/j.bcp.2007.01.009.
- Lin P, Chang H, Tsai W-T, et al. Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol. 2003;31(1):22–30. doi:https://doi.org/10.1080/01926230309746.
- Shimizu Y, Nakatsuru Y, Ichinose M, et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2000;97(2):779–782. doi:https://doi.org/10.1073/pnas.97.2.779.
- Ikuta T, Namiki T, Fujii-Kuriyama Y, et al. AhR protein trafficking and function in the skin. Biochem Pharmacol. 2009;77(4):588–596. https://linkinghub.elsevier.com/retrieve/pii/S0006295208007181. doi:https://doi.org/10.1016/j.bcp.2008.10.003.
- Cauchi S, Stücker I, Cénée S, et al. Structure and polymorphisms of human aryl hydrocarbon receptor repressor (AhRR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Pharmacogenetics. 2003;13(6):339–347. doi:https://doi.org/10.1097/00008571-200306000-00005.
- Zudaire E, Cuesta N, Murty V, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest. 2008;118(2):640–650. doi:https://doi.org/10.1172/JCI30024.
- Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007;581(19):3608–3615. doi:https://doi.org/10.1016/j.febslet.2007.03.046.
- Marlowe JL, Knudsen ES, Schwemberger S, et al. The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. J Biol Chem. 2004;279(28):29013–29022. doi:https://doi.org/10.1074/jbc.M404315200.
- Mandal PK. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol B. 2005;175(4):221–230. doi:https://doi.org/10.1007/s00360-005-0483-3.
- Yin XF, Chen J, Mao W, et al. A selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res. 2012;31:46 doi:https://doi.org/10.1186/1756-9966-31-46.
- Kim DW, Gazourian L, Quadri SA, et al. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000;19(48):5498–5506. doi:https://doi.org/10.1038/sj.onc.1203945.
- Shimba S, Komiyama K, Moro I, et al. Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells. J Biochem. 2002;132(5):795–802. doi:https://doi.org/10.1093/oxfordjournals.jbchem.a003289.
- Moennikes O, Loeppen S, Buchmann A, et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004;64(14):4707–4710. http://www.ncbi.nlm.nih.gov/pubmed/15256435. doi:https://doi.org/10.1158/0008-5472.CAN-03-0875.
- Peng TL, Chen J, Mao W, et al. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol. 2009;10:27–27. doi:https://doi.org/10.1186/1471-2121-10-27.
- Kuznetsov NV, Andersson P, Gradin K, et al. The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene. 2005;24(19):3216–3222. http://www.nature.com/articles/1208529. doi:https://doi.org/10.1038/sj.onc.1208529.
- Wei Y, Zhao L, He W, et al. Benzo[a]pyrene promotes gastric cancer cell proliferation and metastasis likely through the aryl hydrocarbon receptor and ERK-dependent induction of MMP9 and c-myc. Int J Oncol. 2016;49(5):2055–2063. doi:https://doi.org/10.3892/ijo.2016.3674.
- Lai DW, Liu SH, Karlsson AI, et al. The novel aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination. Oncotarget. 2014;5(17):7788–7804. doi:https://doi.org/10.18632/oncotarget.2307.
- Yin X-F, Chen J, Mao W, et al. Downregulation of aryl hydrocarbon receptor expression decreases gastric cancer cell growth and invasion. Oncol Rep. 2013;30(1):364–370. doi:https://doi.org/10.3892/or.2013.2410.
- Laich A, Neurauter G, Widner B, et al. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem. 2002;48(3):579–581. doi:https://doi.org/10.1093/clinchem/48.3.579.
- Richard DM, Dawes MA, Mathias CW, et al. L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2:45–60. doi:https://doi.org/10.4137/ijtr.s2129.
- Mellor AL, Munn DH. Erratum: creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8(2):160–160. http://www.nature.com/articles/nri2264. doi:https://doi.org/10.1038/nri2264.
- Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20(10):469–473. http://www.ncbi.nlm.nih.gov/pubmed/10500295. doi:https://doi.org/10.1016/s0167-5699(99)01520-0.
- Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–774. http://www.ncbi.nlm.nih.gov/pubmed/15459668. doi:https://doi.org/10.1038/nri1457.
- Metz R, DuHadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7087. doi:https://doi.org/10.1158/0008-5472.CAN-07-1872.
- Lob S, Konigsrainer A, Schafer R, et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood. 2008;111(4):2152–2154. doi:https://doi.org/10.1182/blood-2007-10-116111.
- Meininger D, Zalameda L, Liu Y, et al. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors . Biochim Biophys Acta. 2011;1814(12):1947–1954. doi:https://doi.org/10.1016/j.bbapap.2011.07.023.
- Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196(4):447–457. doi:https://doi.org/10.1084/jem.20020052.
- Curran T-A, Jalili RB, Farrokhi A, et al. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology. 2014;219(1):17–24. doi:https://doi.org/10.1016/j.imbio.2013.06.008.
- Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res. 2005;25(1):20–30. doi:https://doi.org/10.1089/jir.2005.25.20.
- Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna)). 2012;119(2):197–209. doi:https://doi.org/10.1007/s00702-011-0681-y.
- Yadav MC, Burudi EME, Alirezaei M, et al. IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007;55(13):1385–1396. doi:https://doi.org/10.1002/glia.20544.
- Chiesa M, Della Carlomagno S, Frumento G, et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108(13):4118–4125. doi:https://doi.org/10.1182/blood-2006-03-006700.
- Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–5943. http://www.nature.com/articles/onc2008267. doi:https://doi.org/10.1038/onc.2008.267.
- Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–1077. doi:https://doi.org/10.1038/sj.cdd.4401073.
- Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363–1372. doi:https://doi.org/10.1084/jem.189.9.1363.
- Muller AJ, Sharma MD, Chandler PR, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA. 2008;105(44):17073–17078. doi:https://doi.org/10.1073/pnas.0806173105.
- Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198. doi:https://doi.org/10.4049/jimmunol.0903670.
- Engin AB, Karahalil B, Karakaya AE, et al. Exposure to helicobacter pylori and serum kynurenine to tryptophan ratio in patients with gastric cancer. Pteridines. 2010;21(1):110–120. doi:https://doi.org/10.1515/pteridines.2010.21.1.110.
- Engin AB, Karahalil B, Karakaya AE, et al. Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer. WJG. 2015;21(12):3636–3643. doi:https://doi.org/10.3748/wjg.v21.i12.3636.
- Latremoliere A, Latini A, Andrews N, et al. Reduction of neuropathic and inflammatory pain through Inhibition of the tetrahydrobiopterin pathway. Neuron. 2015;86(6):1393–1406. doi:https://doi.org/10.1016/j.neuron.2015.05.033.
- Thöny B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J. 2000;347(1):1–16. doi:https://doi.org/10.1042/bj3470001.
- Bendall JK, Douglas G, McNeill E, et al. Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal. 2014;20(18):3040–3077. doi:https://doi.org/10.1089/ars.2013.5566.
- Werner-Felmayer G, Golderer G, Werner E. Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects. Curr Drug Metab. 2002;3(2):159–173. doi:https://doi.org/10.2174/1389200024605073.
- Thöny B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006;27(9):870–878. doi:https://doi.org/10.1002/humu.20366.
- Werner ER, Werner-Felmayer G, Mayer B. Tetrahydrobiopterin, cytokines, and nitric oxide synthesis. Proc Soc Exp Biol Med. 1998;219(3):171–182. http://www.ncbi.nlm.nih.gov/pubmed/9824540. doi:https://doi.org/10.3181/00379727-219-44331.
- Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829–837. doi:https://doi.org/10.1093/eurheartj/ehr304.
- Chen L, Zeng X, Wang J, et al. Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol. 2010;177(5):2671–2680. doi:https://doi.org/10.2353/ajpath.2010.100025.
- Dai Y, Cui J, Gan P, et al. Downregulation of tetrahydrobiopterin inhibits tumor angiogenesis in BALB/c-nu mice with hepatocellular carcinoma. Oncol Rep. 2016;36(2):669–675. doi:https://doi.org/10.3892/or.2016.4850.
- Pickert G, Lim HY, Weigert A, et al. Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer. 2013;132(3):591–604. doi:https://doi.org/10.1002/ijc.27706.
- Lind DS. Arginine and cancer. J Nutr. 2004;134(10 Suppl):2837S–2841S. doi:https://doi.org/10.1093/jn/134.10.2837S.
- Keshet R, Erez A. Arginine and the metabolic regulation of nitric oxide synthesis in cancer. Dis Model Mech. 2018;11(8):dmm033332. http://www.ncbi.nlm.nih.gov/pubmed/30082427. doi:https://doi.org/10.1242/dmm.033332.
- Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res. 2015;21(1):9–17. doi:https://doi.org/10.1007/s12253-014-9860-0.
- Rodriguez PC, Zea AH, DeSalvo J, et al. l-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003;171(3):1232–1239. doi:https://doi.org/10.4049/jimmunol.171.3.1232.
- Albina JE, Caldwell MD, Henry WL, et al. Regulation of macrophage functions by L-arginine. J Exp Med. 1989;169(3):1021–1029. doi:https://doi.org/10.1084/jem.169.3.1021.
- Barbul A, Dawson H. Arginine and immunity. Diet Nutr Immun. 2018;137:199–216.
- Wang Y, Lawson MA, Kelley KW, et al. Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2,3-dioxygenase. Brain Behav Immun. 2010;24(8):1249–1253. doi:https://doi.org/10.1016/j.bbi.2010.04.015.
- Thomas SR, Terentis AC, Cai H, et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide . J Biol Chem. 2007;282(33):23778–23787. doi:https://doi.org/10.1074/jbc.M700669200.
- Kujundžić RN, Lowenthal JW. The role of tryptophan metabolism in iNOS transcription and nitric oxide production by chicken macrophage cells upon treatment with interferon gamma. Immunol Lett. 2008;115(2):153–159. doi:https://doi.org/10.1016/j.imlet.2007.11.003.
- Sullivan LB, Gui DY, Heiden MG. Vander Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer. 2016;16(11):680–693. http://www.nature.com/articles/nrc.2016.85. doi:https://doi.org/10.1038/nrc.2016.85.
- Zou S, Wang X, Liu P, et al. Arginine metabolism and deprivation in cancer therapy. Biomed Pharmacother. 2019;118:109210 doi:https://doi.org/10.1016/j.biopha.2019.109210.
- Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett. 2015;364(1):1–7. doi:https://doi.org/10.1016/j.canlet.2015.04.020.
- Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839–5849. doi:https://doi.org/10.1158/0008-5472.CAN-04-0465.
- Zam W. Arginine enzymatic deprivation and diet restriction for cancer treatment. Braz J Pharm Sci. 2017;53:e00200.
- Albaugh VL, Pinzon-Guzman C, Barbul A. Arginine-dual roles as an onconutrient and immunonutrient. J Surg Oncol. 2017;115(3):273–280. doi:https://doi.org/10.1002/jso.24490.
- Patil MD, Bhaumik J, Babykutty S, et al. Arginine dependence of tumor cells: targeting a chink in cancer’s armor. Oncogene. 2016;35(38):4957–4972. doi:https://doi.org/10.1038/onc.2016.37.
- Tsai CY, Chi HC, Chi LM, et al. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy. Faseb J. 2018;32(5):2601–2614. doi:https://doi.org/10.1096/fj.201700094R.
- Shan YS, Hsu HP, Lai MD, et al. Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. Sci Rep. 2015;5:9783. doi:https://doi.org/10.1038/srep09783.
- Nanthakumaran S, Brown I, Heys SD, et al. Inhibition of gastric cancer cell growth by arginine: molecular mechanisms of action. Clin Nutr. 2009;28(1):65–70. doi:https://doi.org/10.1016/j.clnu.2008.10.007.
- Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol. 2004;22(10):1815–1822. doi:https://doi.org/10.1200/JCO.2004.11.120.
- Lewis ND, Asim M, Barry DP, et al. Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages. J Immunol. 2010;184(5):2572–2582. https://pubmed.ncbi.nlm.nih.gov/20097867. doi:https://doi.org/10.4049/jimmunol.0902436.
- Chaturvedi R, Asim M, Hoge S, et al. Polyamines impair immunity to Helicobacter pylori by inhibiting L-arginine uptake required for nitric oxide production. Gastroenterology. 2010;139(5):1686–1698. doi:https://doi.org/10.1053/j.gastro.2010.06.060.
- Tan J, Guo Y, Applegate TJ, et al. L-arginine regulates immune functions in chickens immunized with intermediate strain of infectious bursal disease vaccine. Jpn Poult Sci. 2015;52(2):101–108. doi:https://doi.org/10.2141/jpsa.0140101.
- Grimble G. Can daily dietary arginine supplement affect the function and subpopulation of lymphocytes in patients with advanced gastric cancer? Clin Nutr. 1994;13(2):127–128. doi:https://doi.org/10.1016/0261-5614(94)90075-2.
- Shu XL, Xu H, Yu TT, et al. Regulation of apoptosis in human gastric cancer cell line SGC-7901 by L-arginine. Panminerva Med. 2014;56(3):227–231.
- Vissers YLJ, Dejong CHC, Luiking YC, et al. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr. 2005;81(5):1142–1146. http://www.ncbi.nlm.nih.gov/pubmed/15883440. doi:https://doi.org/10.1093/ajcn/81.5.1142.